InsidersTradesSigma
Follow the Cantargia AB share price and the full directors' dealings record of the company, a publicly traded company based in Finland. Shares are listed on the FI market, under the authority of FIN-FSA. Operating in the Health Care sector, Cantargia AB has published 3 insider filings. Market capitalisation: €464.7m. The latest transaction was filed on 2 April 2026 (Purchase). Among the most active insiders: David Liberg. The full history is openly available.
3
Insider Decl.
n/a
Thresholds
€26,043
3 ops.
Buy Volume
n/a
n/a
Sell Volume
32Σ signal
Fundamental score
Ranked 3 of 28,932 companies
97.6
score / 100
Value97
Quality98
FCF yld32%
Earn yld32%
EV/EBITDA3.0x
ROE106%
Gross mgn·
Net mgn46%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 April 2026
Declarations3 total
80,000 shares0OptionFI:A003X489-1
20,000 shares@ €0.37770.0009% mcap100.0% of flowAktieISIN SE0006371126FI:A003X308-1
50,000 shares@ €0.36980.0022% mcap100.0% of flowAktieISIN SE0006371126FI:A003X307-1
3 of 3 declarations
About Cantargia AB
Cantargia AB is a Swedish biopharmaceutical company focused on developing treatments for cancer and inflammatory diseases. It is listed on the Stockholm Stock Exchange.